Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial
2020; Nature Portfolio; Volume: 26; Issue: 10 Linguagem: Inglês
10.1038/s41591-020-1081-3
ISSN1546-170X
AutoresNirav N. Shah, Bryon D. Johnson, Dina Schneider, Fenlu Zhu, Anikó Szabó, Carolyn A. Keever-Taylor, Winfried Krueger, Andrew Worden, Michael J. Kadan, Sharon Yim, Ashley M. Cunningham, Mehdi Hamadani, Timothy S. Fenske, Boro Dropulić, Rimas J. Orentas, Parameswaran Hari,
Tópico(s)Silicon Carbide Semiconductor Technologies
Referência(s)